EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Clinical outcome of eplerenone in the management of acute central serous chorioretinopathy

Pramod Kumar Sharma, Bhagyashree Padhan, Ipsita Khuntia, Madhumita Naik, Biswambara Satpathy

Oman Journal of Ophthalmology · 2025-01 · 18 (1) · 9-15

DOI: 10.4103/ojo.ojo_118_23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oman Journal of Ophthalmology, online erschienen am 25.02.2025. Verfasst von Pramod Kumar Sharma und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, VIMSAR, Burla, Sambalpur, Odisha, India. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To evaluate the clinical outcomes of eplerenone in the management of acute central serous chorioretinopathy (CSCR). MATERIALS AND METHODS: This case–control study involved 52 eyes of 52 cases of acute CSCR divided between treatment (26) and control (26) groups. Cases in the treatment group were managed by tablet eplerenone 50 mg/d. During the scheduled visits, serum electrolytes and an ophthalmic evaluation, including optical coherence tomography, were conducted. The control group was subject to observation and a similar follow-up. The Statistical Programme for Social Sciences, version 23 was used for statistical tests. RESULTS: The mean age in the treatment and control group was 39.15 ± 12.1 years and 36.1 ± 8.09 years, respectively. In the treatment group, 46.15% of right eyes and 53.8% of left eyes, and in the control group, 61.5% of right eyes and 38.5% of left eyes were evaluated. Visual acuity improved to 6/6 in 96.2% of treated cases and 19.2% of controls in the 2 nd month of follow-up. Subretinal fluid resolved completely in 61.52% of treated cases and 38.46% of controls at 12-week follow-up. No adverse events were reported, and by the 12 th week of follow-up, the mean serum K+ was 4.80 ± 0.157 mEq/L. CONCLUSION: Acute CSCR cases managed with oral eplerenone can attain faster resolution with significant functional improvement. Eplerenone may serve as a first-line therapeutic option for acute CSCR with a better safety profile.

Schlagwörter

Stichwörter der Autor:innen

Acute central serous chorioretinopathycentral macular thicknessmineralocorticoid antagonistoptical coherence tomographysubretinal fluid

Autor:innen und Institutionen

  • Department of Ophthalmology, VIMSAR, Burla, Sambalpur, Odisha, India.
  • Department of Ophthalmology, FM Medical College, Balasore, Odisha, India.

Zitieren

APA

Sharma, P. K., Padhan, B., Khuntia, I., Naik, M., & Satpathy, B. (2025). Clinical outcome of eplerenone in the management of acute central serous chorioretinopathy. Oman Journal of Ophthalmology, 18(1), 9-15. https://doi.org/10.4103/ojo.ojo_118_23

Vancouver

Sharma PK, Padhan B, Khuntia I, Naik M, Satpathy B. Clinical outcome of eplerenone in the management of acute central serous chorioretinopathy. Oman Journal of Ophthalmology. 2025;18(1):9-15. doi:10.4103/ojo.ojo_118_23

BibTeX
@article{Sharma2025,
  author = {Sharma, Pramod Kumar and Padhan, Bhagyashree and Khuntia, Ipsita and Naik, Madhumita and Satpathy, Biswambara},
  title = {Clinical outcome of eplerenone in the management of acute central serous chorioretinopathy},
  journal = {Oman Journal of Ophthalmology},
  year = {2025},
  volume = {18},
  number = {1},
  pages = {9--15},
  doi = {10.4103/ojo.ojo_118_23}
}
Kostenlos starten →